Back to report

Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversion

ZBHResearch reportPosted by Goglides ResearchMay 20, 2026
NYSEZBHCoverage BootstrapZimmer Biomet Holdings, Inc.

Thesis summary

ZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.

View article

ZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.

View full article

Discuss the thesis

0 comments
Commenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.

No comments yet. Start the discussion with evidence, a question, or a bear case.